CurtilandDevilleJr.MD

Sarcoma, Urologic Cancer

Associate Professor, Radiation Oncology, Johns Hopkins University

Dr. Deville is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

I am a radiation oncologist with Johns Hopkins Kimmel Cancer Center at Sibley Memorial Hospital, medical director of the Johns Hopkins Proton Therapy Center at Sibley and associate professor of radiation oncology and molecular radiation sciences with the Johns Hopkins School of Medicine. My areas of clinical practice are genitourinary malignancies, including prostate cancer, and soft tissue sarcomas. I have a special interest in effective treatment of prostate cancer with proton therapy and serve as a site primary investigator for the Prospective Comparative Study of Outcomes With Proton and Photon Radiation in Prostate Cancer (COMPPARE).

University of Pennsylvania Health SystemResidency, Radiation Oncology, 2006 - 2010
MedStar Health/Harbor HospitalInternship, Transitional Year, 2005 - 2006
The Warren Alpert Medical School of Brown UniversityClass of 2005

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

PubMed

145 citations
Improving Diversity, Inclusion, and Representation in Radiology and Radiation Oncology Part 1: Why These Matter
Johnson B. Lightfoote, Julia R. Fielding, Curtiland Deville, Richard B. Gunderman, Gail N. Morgan
Journal of the American College of Radiology. 2014-07-01
4 citations
Long-term Clinical Outcomes in Favorable Risk Prostate Cancer Patients Receiving Proton Beam Therapy.
Alicia Bao, Andrew R Barsky, Russell Maxwell, Justin E Bekelman, Stefan Both
International Journal of Particle Therapy. 2022-01-01
656 citations
Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial
Ryan Phillips, William Shi, Matthew P. Deek, Noura Radwan, Su Jin Lim
JAMA Oncology. 2020-05-01

Journal Articles

Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results from the Internationa...
Michael J Zelefsky, Matthew R Cooperberg, Brian J Davis, Eric M Horwitz, Martha K Terris, Christopher L Amling, Christopher J Kane, Curtiland Deville, Theodore L Dewee..., JAMA Oncology

UPDATES FROM ASTRO’S COMMITTEE ON HEALTH EQUITY, DIVERSITY AND INCLUSION (CHEDI)7/24/2018
Biochemical Results, Toxicity, and Quality of Life After Delivery of Dose-Escalated Image-Guided Proton Therapy for Prostate Cancer5/3/2016

IMRT vs Proton Therapy for Early Prostate Cancer?October 1st, 2024
Dr. Howard Sandler Voted President-Elect of the American Society for Radiation Oncology (ASTRO)July 13th, 2022
Johns Hopkins Medicine Celebrates Opening of the Johns Hopkins National Proton Center at Sibley Memorial Hospital, in Collaboration with Children’s NationalOctober 28th, 2019
Join now to see all